Cargando…
Discovery of Desmuramylpeptide NOD2 Agonists with Single-Digit Nanomolar Potency
[Image: see text] The innate immune receptor nucleotide-binding oligomerization-domain-containing protein 2 (NOD2) represents an important target for the development of structurally defined small molecule immunomodulatory compounds that have great potential to be used either as vaccine adjuvants or...
Autores principales: | Guzelj, Samo, Bizjak, Špela, Jakopin, Žiga |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377006/ https://www.ncbi.nlm.nih.gov/pubmed/35978688 http://dx.doi.org/10.1021/acsmedchemlett.2c00121 |
Ejemplares similares
-
Structural Fine-Tuning
of Desmuramylpeptide NOD2 Agonists
Defines Their In Vivo Adjuvant Activity
por: Guzelj, Samo, et al.
Publicado: (2021) -
Lipidation of NOD2 Agonists with Adamantane and Stearoyl Moieties Differentially Regulates Their In Vivo Adjuvant Activity
por: Guzelj, Samo, et al.
Publicado: (2022) -
Covalently
Conjugated NOD2/TLR7 Agonists Are Potent
and Versatile Immune Potentiators
por: Guzelj, Samo, et al.
Publicado: (2022) -
Novel Scaffolds for Modulation of NOD2 Identified by Pharmacophore-Based Virtual Screening
por: Guzelj, Samo, et al.
Publicado: (2022) -
Synthesis of Conformationally Constrained d-Glu-meso-DAP Analogs as Innate Immune Agonists
por: Guzelj, Samo, et al.
Publicado: (2020)